# Index

Abbott, A. 131, 136, 168, 195  
adverse drug reaction (ADR) 41, 49  
reporting systems 54, 57, 67, 87, 91  
reports 7, 53, 59, 82, 91, 98, 156  
side-effects 5, 8, 12, 13, 16, 17, 37,  
82, 83, 89, 91, 99, 107, 139, 142,  
143, 148, 152, 153, 170, 183,  
194, 195, 197, 203  
signal of 12, 38, 43, 67, 73, 75, 77,  
82, 85, 87, 95, 154, 180, 181  
spontaneous notification 55, 56, 86,  
87, 90, 91, 108, 173, 194, 207  
Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)  
83, 85  
American Medical Association (AMA)  
67  
Bauman, Howard 114, 124–6, 131–2,  
135  
Bayer 84, 85, 94  
Ben-David, J. 25  
boundary-organisations 34  
Bovine Spongiform Encephalopathy (BSE) 39, 44, 45, 46, 47, 70, 73,  
165, 166  
Boyle, Robert 29, 32, 208  
Braithwaite, J. and Drahos, P. 8, 20  
Brunsson, N. 10, 18, 33  
Cambrosio, A. 214  
Carpenter, D. 17, 73  
Cerivastatin 84–6, 92–8, 106, 153, 194,  
196, 205; see also Lipobay  
Chipping Campden 129  
circulation  
as defining experts 32  
as professional mobility 29  
between activities of control 33  
between evaluation and standard-setting 33  
invisibility of 11  
measurement of 28  
multi-professionalism and 169–71  
of drug safety experts 78, 99, 102,  
107  
of HACCP experts 119, 137,  
139–40  
of PMM experts 159, 161  
transnationalisation and 177–81  
clinical pharmacology  
as evaluative science 12, 37  
as experimental science 48–50; see also clinical trials  
co-word analysis of 57–8  
dose-response assessment and 48,  
57, 58  
drug regulation in the USA and  
66–7  
efficacy 48–50, 54, 58, 66, 67, 211,  
212  
history of 74  
pharmacovigilance and 53  
statistics and 56  
clinical trials; see also marketing  
authorisation  
as experiment 48–50  
as tool of qualification 37  
clinical pharmacology and 74  
for functional or novel foods 143  
generalisation of 41  
limits of 53–9, 77, 90, 98  
safety data from 14, 102, 106  
Codex Alimentarius (Codex)  
as receptacle of expert work  
125–30  
as standard setting organisation 33  
as WTO reference body 75  
Codex Committee on Food Hygiene  
128, 129  
Codex principles for risk analysis  
and EU food law 70

255
consensus on HACCP and 134–40
International guideline for HACCP 14, 112–22
members of ICMSF and 132
risk assessment and 69
setting of critical control points and 129–30
Committee for Proprietary Medicinal
Products (CPMP) 41, 73, 88, 178; see also Committee for Human
Medicinal Products (CHMP)
Committee for the Safety of Drugs
(CSD) 67
Conference for the International
Organization of Medical Sciences
(CIOMS) 98, 101, 102–5, 108–9, 167, 177, 178, 181–3, 186–7, 193, 207; see also International
Conference on Harmonisation
(ICH)
consensus
consensus conferences 15, 169
consensus, manufacturing of 11, 34, 134, 135, 137, 187
conventional foods 144, 145, 151, 212
Council of Ministers of the European
Union 46
co-word analysis 57, 61, 63, 213, 214
Crane, D. 29–31, 34
Crestor 153
Daemmrich, A. 73
development safety update report
(DSUR) 102
Directorate General XXIV 74; see also
Directorate General for Health
and Consumer Protection
Directorate General for Health and
Consumer Protection (DG
SANCO) 45, 70, 161; see also DG XXIV
Djelic, M.-L. and Sahlin-Andersson K.
(eds.) 9
drug safety
CIOMS and ICH 178, 182, 183
clinical pharmacology and 53
clinical trials and 56–9
drug safety and PVP 78–83
drug safety experts 14, 86, 89, 92–4, 98, 99, 102, 107–9, 173, 193, 196–7, 201, 202, 205
scientists’ conception of 66
Drug Safety Research Unit (DSRU) 86
drug withdrawal
as result of pharmacovigilance
activities 72
Cerivastatin 84–6, 88; see also Lipobay
periodic safety update report and 196
PVP and avoidance of 12
risk management and 94–7
series of 77–8
worldwide withdrawals of Vioxx and Lipobay 43
due diligence 123, 138
European Commission
as international policy-making
organisation 33
CIOMS and 182
European Medicines Evaluation
Agency and 67
HACCP and 113, 118–22, 128, 137, 143
New Approach 118, 119, 128
Novel foods and 146, 147, 150, 153, 155, 161, 165
Elixir Sulfanilamide 39, 91
European Medicines Evaluation
Agency (EMEA); see also regulatory agencies
creation of 41
Gabriel and meetings at 177
globalisation of pharmaceutical
regulation and 209
marketing authorisation decisions 195
pharmacovigilance missions 43
risk management guidelines 78, 80, 83, 84, 193, 195
risk management strategy 95–6
Environmental Protection Agency
(EPA) 16, 64
European Medicines Agency (EMA);
see European Medicines
Evaluation Agency (EMEA)
Index

epidemiology
  combination with toxicology 64
  detection of regularities 54
  epidemiological surveillance 7, 47, 69, 72, 209
  epidemio-surveillance 12
  imputation and 62
  pharmacoepidemiology and 196
  post-marketing surveillance and 68
  safety specification and 80
epistemic community 11, 19–21, 24–6, 28, 35–6, 189
EudraVigilance 96
European Federation of Pharmaceutical Industries and Associations (EFPIA) 102, 178
European food law 43–7, 64, 70, 119, 121, 128, 144
European Food Safety Authority (EFSA); see also regulatory agencies
  coordination of surveillance plans 60
  creation of 47
  data collection mission 47
  International Life Science Institute and 161, 206
  members of EFSA panels 159, 160, 178
  production of risk assessment opinions 47
  recommendation on post-market monitoring studies 150
European official guidelines on pharmacovigilance for medicinal products for human use (the ‘Volume 9’) 80
European Parliament 45, 46, 47, 73, 74, 94, 146, 165
evaluation
  as science 12, 15, 32, 35, 37, 38, 48, 169, 173, 183
  regulation 196, 208
  standard-setting and 11, 99, 108
Evans, Stephen 86, 87, 88, 89, 90, 93, 98, 99; see also Waller, Patrick
Expert; see also scientists
  cooptation 76, 125, 135, 174, 183
hybridisation of expertise 197
industry advice 33, 132, 139, 187
label of expert 171, 188
prestige 20
quasi-regulators 107, 108, 188
recruitment 131, 134, 135, 158, 182
scientific advice 4, 36, 44, 45, 73, 167, 168, 174, 175, 180, 189
occupationalisation of 174
transnationalisation of experts’ career 177, 181, 188
Federal Food Drug and Cosmetic Act 39
Fischer, F. 206
Food and Agricultural Organization (FAO) 70, 113, 131, 132, 135, 151, 159, 178
Food and Chemical Toxicology (FCT) 142, 143, 147, 149, 155
Food and Drug Administration (FDA) 39, 40, 64, 66, 67, 68, 73, 74, 86, 89, 93, 110, 113, 125, 131, 150
food hygiene
  as research area 169, 171
  Codex Committee on Food Hygiene 128, 129
  consultants 130
  criteria 113
  end of chain control 112–14
  European Directives 118
  food microbiologists and 131
  food microbiology and 52, 62
  fragmentation of 14
  large businesses and 199
  liberalisation 198
  local regimes 123
  performance-based 139
  promotion of industrial food hygiene 125
  regulation of 1, 12, 201, 202
food microbiology
  co-word analysis of 63–4
  elite of 131, 134, 169, 170, 173, 189, 202
  food regulation and 202
  industry support 64, 176
  journals of 126
  limits of 65
  microbiology and 52
Scientists and the regulation of risk

professional jurisdiction of 131
reorientation of 130
food safety; see also risk assessment
food additives 2, 5, 46, 50–51, 60, 61, 62, 68, 69, 74, 147, 151, 159, 162, 176
food surveillance 12, 60, 65
food zoonoses 47
food-borne diseases 39, 136
White Paper on Food Safety 45
functional foods 46, 144–7, 150, 152, 156, 158, 159, 162, 163, 212
functional efficacy 144, 148
Funtowicz, S. and Ravetz, J. 2
Gabriel 99, 102–9, 172, 177, 178, 181, 182, 183, 190, 193, 194, 196
General Agreement on Tariff and Trade (GATT) 70
General Food Law 46, 47, 64, 70, 119, 144; see also European food law;
European Food Safety Authority (EFSA)
global knowledge network 19, 23; see also network concept
Gold, Harry 56, 74
guidance
as source 213
for HACCP 113, 114, 116, 125, 126, 128, 131
for PMM 142, 149, 156, 163, 164, 203
for PVP 83
generic guidance 120
inducement of change in industry 103
normative pyramid 150
risk management 99
soft law 18
Haas, P. 20–21, 24–26
Hazard Analysis Critical Control Point (HACCP)
audit and 120, 121
critical control points (CCP) 112, 115, 125, 131, 134–8
critical control points, determination of 127–8
critical failure areas concept and 124
decision-tree 75, 118, 126, 127, 129, 134
developing countries and 136, 209
HACCP-like approaches and systems 112, 113, 123, 139, 140
hazard analysis 115, 122, 123, 127, 136, 149
ISO and 116, 128, 138
local vs. central establishment of critical control points 121–3, 130
logic sequence 116, 117, 129, 134
manuals 35
negotiation of critical control points 123, 139
philosophy 121, 127
policy panacea 115
principles 112
quality assurance 120, 122, 130, 131, 132, 172, 180, 187, 201, 213
regulatory concept 12, 13, 14, 15
reliability 124, 199
risk analysis 199
systems thinking 124, 199
total quality management and 128
translation 136
Heads of Agencies (HOA) 73, 95, 96, 107, 110
Heads of Medicines Agencies (HMA): see heads of agencies (HOA)
Hill, Bradford 56
imputation, research programme of 12, 17, 37–8, 46–7, 52, 55–6, 60, 63–4, 71–2, 76, 202, 213; see also evaluation
Inman, William 56, 67, 86
inspectors
as actors of regulatory intervention 213
as consultants and auditors 121
as regulatory intermediaries 130
complexity of the role of 198, 199
food microbiologists and veterinarians as 202
HACCP plans and external inspectors 113, 120
National Advisory Committee on Microbiological Criteria for Foods (NACMCF) and 126
negotiation with 123, 139
self-control and 119
sharing of information with 9
surveillance of food contaminations 7
training of food inspectors 125
interest groups 24
International Commission for the Microbiological Safety of Food (ICMSF) 69, 76, 125–9, 130, 131–5, 137, 139, 176, 177, 178, 181, 183, 186, 198, 201, 207
International Conference of Harmonisation (ICH) 33, 77, 78, 79, 81, 83, 84, 88, 97–9, 101–5, 107–10, 167, 177, 178, 181, 193, 209; see also Council for the International Organization of the Medical Sciences (CIOMS)
interstitial organisations 15, 34, 169, 181–6, 188, 189, 207, 208
invisible college
as club 183, 189
benefits of using the notion of 11, 19, 31–4
big players and 139
embeddedness in regulation 103–4
frontiers 161–3, 204
HACCP principles and 114
history of the 29
junction between evaluation and standard-setting 11, 99, 108; see also evaluation
manufacturing of consensus 134
occupational diversity in 172
PMM experts as 159
scientometrics and 29–30
Jasanoff, S. 2, 171
Jean-Claude 132, 176–8, 186–8, 199
John 158, 161, 163, 178, 187
Joint Expert Committee for Food Additives (JECFA) 68, 69, 70, 178
Kefauver, Senator Carey Estes 40
Keohane, R. 21, 25
Knorr-Cetina, K. 26, 27, 27
Koch, Robert 52
Lachance, Paul 124
Lezaun, J. 7
liability 17, 43, 56
life-style medicines 86, 95
Lipobay 43, 97, 110, 153; see also cerivastatin; drug withdrawal
marketing authorisation
as a type of control 47
European Union procedures for 40–43
for food products 46, 68
for novel foods 149, 150, 152
of me-too drugs 86
phytosterol esters 153
positive list and 68
pre-marketing tests 13, 56, 145, 147, 195
revision of 87, 98
submission of risk management plan and 81
Marks, H. 48, 66, 71, 73
medicines agencies
blaming of 94
Medicines and Health products Regulatory Agency (MHRA) 73, 76; see also Medicines Control Agency (MCA)
Medicines Control Product Agency (MCA) 73, 86, 88, 89, 101, 107, 110, 167, 172, 177, 193, 206
organisation 82, 83, 156
Merck 96, 97
me-too medicine 5, 17, 84, 85, 86, 95
Meyer, J. 192
Michael 132, 140, 172, 176, 177, 178, 186, 199
microbiology
as scientific discipline 176, 201
microbiological risk assessment 37, 65, 69, 199
Ministry of Agriculture, Food and Fisheries (MAFF) 151, 152
Modell, Walter 74
Mogoutov, Andrei 214
multi-professionalism: see scientists
Scientists and the regulation of risk

National Advisory Committee on Microbiological Criteria for Foods (NACMCF) 126, 129, 131
National Aeronautics and Space Administration (NASA) 112, 124, 131, 186, 198, 199
National Research Council (NRC) 3, 64, 70, 126, 166, 199
Nestlé 126, 129, 132, 145, 176

network concept
embedded knowledge network 23
global knowledge network 19, 23
global public policy networks 22
network of professionals 20, 21, 24
transnational policy networks 22
Nicolas 159, 161, 163, 175, 176, 187, 189
non-governmental organisations 20, 161, 210

novel foods
as regulatory domain 1
European novel food regulation 146, 147, 150, 153, 165, 166
experience of 15
pre-market regulation and 46, 68
post-market monitoring and 142, 158–66
regulatory definition 144–52
regulatory terminology 146
research interest 156
researchers in 169
side-effects of 8, 13, 14

Olestra 154
Organisation for Economic Cooperation and Development (OECD) 159, 161, 178

Parmar, I. 23
Pasteur, Louis 52
Patrick 159, 161, 163, 176, 190
Periodic Safety Update Report (PSUR) 98, 99, 102, 195, 196
pharmaceutical industry 41, 49, 67, 102, 179, 182, 207, 211

pharmacoepidemiology 57, 67, 69, 74, 86, 89, 91, 196
pharmacovigilance
additional pharmacovigilance activities 80
audit 82, 87, 96, 196
centralised procedure and 40, 41
definition of 17
drug monitoring 57, 59, 73, 101
French school of pharmacovigilance 43
industrial pharmacovigilance 177, 194, 195, 197
national pharmacovigilance systems 42, 43, 67, 90, 108
pharmacovigilance responsible person 82, 102, 170, 172
public health and 86–8, 92, 93, 97, 98, 99, 103, 107, 196
regulatory philosophy 93
safety databases 35, 64, 65, 75, 83, 90, 194
terminology 102
phase IV studies 43, 81
phocomelia 42, 59, 90; see also adverse drug reaction
phytosterol esters 152–5, 159, 163, 166
Pillsbury 14, 112, 114, 124, 125, 126, 131, 139, 140, 186, 198, 199
post-market monitoring (PMM)
consumer targeting 155
dose exposure 153
exposure assessment guidance for 142–3
International Life Science Institute (ILSI) and 158–63
post-launch monitoring (PLM) and 152, 153, 154–5, 156, 157, 163
post-marketing surveillance (PMS) and 156, 157
reassurance 8, 148
regulatory concept 12, 13, 14, 15, 150–57
risk analysis principle 199–200
risk assessment 143–9, 153, 157, 158
scope 143, 148, 153, 164, 165, 202, 203
policy enterprise 20, 24, 39
Porter, T. 7, 18
<table>
<thead>
<tr>
<th>Index</th>
<th>261</th>
</tr>
</thead>
<tbody>
<tr>
<td>post-normal science 2</td>
<td>regulatory agencies</td>
</tr>
<tr>
<td>practolol 55, 91</td>
<td>agencification 206</td>
</tr>
<tr>
<td>Price, D. J. de S. 29–31, 34</td>
<td>as nodal point of invisible colleges 205</td>
</tr>
<tr>
<td>Procter &amp; Gamble 154</td>
<td>as risk assessment agencies 6</td>
</tr>
<tr>
<td>Prodi, Romano 45</td>
<td>circulation of scientists and 11</td>
</tr>
<tr>
<td>pharmaceutical risk management 83, 84, 96, 97, 194, 196</td>
<td>creation of the European Food Safety Authority 47</td>
</tr>
<tr>
<td>blame avoidance and 94, 96, 99, 106</td>
<td>creation of the European Medicines Evaluation Agency 41</td>
</tr>
<tr>
<td>FDA risk management 95–6</td>
<td>democratic record of regulatory agencies 209–10</td>
</tr>
<tr>
<td>pharmacovigilance planning (PVP) agencies’ reorganisation and 79, 82, 83</td>
<td>sharing of information 9</td>
</tr>
<tr>
<td>as research area 169</td>
<td>regulatory authority 157, 181</td>
</tr>
<tr>
<td>changes linked to the introduction of 79, 83</td>
<td>regulatory concepts 1, 8, 10</td>
</tr>
<tr>
<td>data requirements and 80</td>
<td>as typifications 5–7</td>
</tr>
<tr>
<td>European Union guideline 81</td>
<td>conceptual power 17; see also Carpenter, D.</td>
</tr>
<tr>
<td>ICH guideline 79, 80, 81</td>
<td>impact of 191–204</td>
</tr>
<tr>
<td>pre-/post-marketing division 82, 83</td>
<td>regulatory concepts as objects of research 178, 179</td>
</tr>
<tr>
<td>pharmaceutical companies’ reorganisation and 83, 191</td>
<td>regulatory concepts as standards 11, 35, 189</td>
</tr>
<tr>
<td>pharmacovigilance specification 12, 78, 79, 81, 88–90, 92, 94, 99, 101, 109, 193, 194</td>
<td>regulatory space 8, 29</td>
</tr>
<tr>
<td>public health and 196</td>
<td>risk 1–8, 16, 75</td>
</tr>
<tr>
<td>regulatory concept 12, 14, 77–9, 89, 90</td>
<td>hazard 2, 46, 60, 63, 64, 65, 75</td>
</tr>
<tr>
<td>risk management and 97, 98, 167</td>
<td>quantitative dose–response assessment 65</td>
</tr>
<tr>
<td>risk management plans 78, 79, 81, 103, 194</td>
<td>risk analysis as science 2, 3, 16, 17, 60, 64</td>
</tr>
<tr>
<td>risk minimisation 77, 78, 81, 95, 106, 183</td>
<td>risk analysis principle 45, 47, 70</td>
</tr>
<tr>
<td>risk reduction 196</td>
<td>risk assessment 2–6, 10, 12, 16, 17, 27, 45, 47, 61, 64–5, 70</td>
</tr>
<tr>
<td>safety specification 80, 124, 203</td>
<td>risk assessment/risk management terminology 164</td>
</tr>
<tr>
<td>physicians hospital physicians 172, 173</td>
<td>risk perception 3</td>
</tr>
<tr>
<td>physicians and national pharmacovigilance systems 53–6</td>
<td>risk regulation approaches of 17</td>
</tr>
<tr>
<td>physicians and reporting of adverse drug reactions 67, 69, 77, 82, 156, 205</td>
<td>as set of activities of control 6–7</td>
</tr>
<tr>
<td>qualification, research programme of 12, 47–53; see also evaluation; imputation</td>
<td>prioritising risks 3</td>
</tr>
<tr>
<td>Quorn 151, 152</td>
<td>regulatory failure 15, 84, 98, 192, 196, 197, 206, 207</td>
</tr>
<tr>
<td>Rank Hovis McDougall (RHM) 151</td>
<td>regulatory rationalisation 212</td>
</tr>
<tr>
<td>Red Book 64</td>
<td>risk regulation regimes 211</td>
</tr>
<tr>
<td></td>
<td>as systems of control 191, 193, 205, 206, 207</td>
</tr>
<tr>
<td></td>
<td>Royal Society of London for the improvement of natural knowledge 29, 36</td>
</tr>
</tbody>
</table>
Scientists and the regulation of risk

Royer, René-Jean 58, 93, 105, 173, 174, 183

Sanitary and Phytosanitary Measures (SPS) 70, 116, 129, 140
Santer, Jacques 73, 74, 165
Sauer, Fernand 73, 209
scientific committee for food (SCF) 76, 153, 154, 158, 159, 163, 178
scientific community, concepts of; see also epistemic community; invisible college
community of thought 20
core-sets 26, 27
research networks 26
scientific communities 5, 23, 24, 25, 27
thought collectives 25
trans-epistemic arenas 26
scientific disciplines 20, 24, 32, 48
history of scientific disciplines 213
experiments
industry experiments 1, 13, 30, 33, 142, 150, 158, 192, 203, 205
scientific experiments 48, 50, 52, 54, 56, 58, 64, 66, 71, 72
scientists
accumulation of positions 143, 159, 171–2, 178, 180
disciplines and professionalisation of scientists 170, 171, 173, 174, 181
medical scientists 53, 99, 104, 105, 106, 107, 109, 163; see also drug safety scientists
multi-professionalism 11, 169, 191
physicians and 1, 7, 17, 33, 41, 42, 49
professional jurisdiction 168, 195, 196
professional rationalisation 175
professional trajectories of 31, 179
scientific elite 1, 11, 14, 19, 29, 32, 35, 39
social authority 11, 15, 20, 23, 27, 32, 34
training as physicians 172, 173
scientisation 10
rationalisation and 192, 204, 212
Scott, J. 5–7
Selznick, P. 8, 17
Slaughter, A.-M. 21

Society for Risk Analysis (SRA) 16
standardisation
as emergent action 204
boundaries of 158, 164
invisible colleges of 29–34
science-driven 10
standard-setting and 18
standard-setting organisations
as sites of scientists’ circulation 11, 176, 177
drug safety experts and 14, 99, 102, 109
International Life Science Institute (ILSI) as 161
New Approach and 119, 147
statins 17, 84, 85, 86, 92, 93, 98, 153, 195
Stockholm Centre for Organizational Research (SCORE) 10
Stone, D. 23, 28
thalidomide 39–42, 49, 54, 58, 59, 81, 87, 90, 91
theorisation 13, 15
abstraction 13, 158, 201
lesson drawing 13, 89, 96, 107, 109
regulatory modelling 13, 112, 113, 138, 199, 200
toxicology 12, 37, 48–52
allowable daily intake (ADI) 51, 74
dose-response and toxicology 61, 64, 65
food toxicology 50, 52, 64, 65, 68, 69
reference dose 69
relations with industry 64
transboundary risk management 9
transnational
transnational and the global 9
transnational policy networks 22; see also network concept
transnational regulation 10, 11, 19, 22, 123, 134, 181, 188, 208
transnational risk regulation 8, 167
transnationalisation of experts’ career 177, 181, 188
trans-science 2, 37
Truhaut, René 51, 59, 68, 69, 74

uncertainty 2, 3, 12, 20, 26, 27, 37, 48, 52, 54, 59, 64, 71
Index

Unilever 152–6, 158, 159, 163, 166, 187, 203
Uppsala Monitoring Centre (UMC) 92, 101

veterinarians 7, 51, 69, 121, 131, 136, 137, 201, 202
viox 43, 96, 110

Weinberg, A. 2

World Health Organization (WHO) contribution to pharmacovigilance planning 86, 89
Council of International Organisation of Medical Sciences and 102, 182

endorsement of HACCP 113, 114, 125, 186
food safety department 136
global food safety challenges 116
International Commission for the Microbiological Safety of Foods and 129, 131, 132, 134, 135
national pharmacovigilance systems and 42, 104, 107
Patrick and 178
quantitative dose-response assessment and 65
risk analysis and 70

World Trade Organization (WTO) 75, 113, 116
Worsley, Benjamin 29